Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a

Conclusion No new signal relating specifically to increased frequency of TMA/TTP-HUS with HSA-free subcutaneous interferon β-1a was detected and no additional risk mitigation measures are required regarding the different formulations. The benefit–risk balance of subcutaneous interferon β-1a remains positive, and routine pharmacovigilance monitoring is appropriate. Funding Ares Trading SA, Aubonne, Switzerland, a subsidiary of Merck Serono SA.

http://link.springer.com/10.1007/s12325-015-0212-6

Source: Advances in Therapy - May 20, 2015 Category: Drugs & Pharmacology Source Type: research